

Review Article

Open Access

Para-Testicular Mesenchymal Chondrosarcomas: an Updated Review of Clinical Insights and Therapeutic Considerations

Carlos Alberto Cardenas^{1*} and David Rosero²

¹Research Department, FORESC (Foundation for Research and Sciences), USA

²Research, UCR (University of California-Riverside), USA

ABSTRACT

Para-testicular mesenchymal chondrosarcoma, an uncommon malignancy originating in the para-testicular region, poses distinctive diagnostic and therapeutic challenges. This comprehensive review offers insights into its incidence, epidemiology, clinical presentation, histopathological features, diagnostic methods, treatment strategies, and prognosis. The recent WHO classification for Soft Tissue Tumors and Bone is a pivotal tool in refining pathologic diagnoses and therapeutic decisions. Notably, the inclusion of skilled clinicians' insights underscores the pivotal role of accurate pathologic diagnoses in guiding treatment choices. Advancements include risk assessment for solitary fibrous tumors, the recognition of NTRK-rearranged soft tissue tumors as an "emerging entity," and the classification of undifferentiated round cell sarcomas. The tumor's rarity, intrinsic and technological complexities, and limited educational impact contribute to the intricate landscape of diagnosis and treatment for mesenchymal tumors.

*Corresponding author

Carlos Alberto Cardenas, Research Department, FORESC (Foundation for Research and Sciences), USA, E-mail: Karmed@live.com.
ORCID: <https://orcid.org/0000-0001-5061-7509>.

Received: August 10, 2023; **Accepted:** August 17, 2023; **Published:** August 27, 2023

Epidemiology and Incidence

Paratesticular mesenchymal chondrosarcomas are infrequent, primarily originating from the spermatic cord, and exhibit aggressive behavior.

Patients often present with a painless para-testicular mass. Histopathological examination, supported by immunohistochemical markers, remains the gold standard for diagnosis.

Tumor's unique histological composition poses diagnostic challenges, while molecular studies offer potential avenues for targeted therapies.

Surgical resection remains the cornerstone of managing these sarcomas, given their metastatic potential. Unfortunately, the prognosis remains unfavorable, underscoring the need for early detection and aggressive interventions.

Understanding the complexities of para-testicular mesenchymal chondrosarcoma is vital for clinicians and pathologists to facilitate early detection and optimal management. This review highlights the tumor's rarity, emphasizing the importance of increased awareness among healthcare professionals to enhance patient outcomes.

Introduction

Para-testicular mesenchymal chondrosarcoma is a rare variant of chondrosarcoma that arises within the para-testicular region [1]. Despite its infrequency, this malignancy presents diagnostic

difficulties due to its biphasic histological pattern comprising undifferentiated small blue cells and mature hyaline cartilage. This review aims to provide a comprehensive analysis of the para-testicular mesenchymal chondrosarcomas exploring their distinctive features, classification, epidemiology, clinical presentation, diagnostic challenges, management options, prognostic implications, and Mental health [2-7].

Classification

Mesenchymal tumors pose a complex challenge within the domain of diagnostic pathology. Improving classification systems is instrumental in enhancing the precision of pathologic diagnoses and, consequently, refining therapeutic strategies. A significant advancement in this direction has been marked by the recent publication of the 2020 WHO classification for Soft Tissue Tumors and Bone [8]. Notably, this edition benefits from the insights of skilled clinicians, who emphasize the pivotal role of accurate pathologic diagnoses in guiding effective treatment choices. Within this comprehensive update, noteworthy enhancements have been implemented.

A risk assessment framework has been introduced to better prognosticate solitary fibrous tumors. Furthermore, the inclusion of NTRK-rearranged soft tissue tumors as an "emerging entity" reflects the evolving therapeutic landscape, accompanied by deliberations on the definitions of "tumor entity" and the implications of a "pathology agnostic" approach in precision oncology [9]. Differentiating undifferentiated round cell sarcomas from Ewing sarcoma and classifying them into three primary subgroups (CIC,

BCLR, and non-ETS fused sarcomas) based on underlying gene rearrangements is a distinctive advancement that aligns with their distinct clinicopathologic profiles. Remarkably, the uniform addressing of entities such as gastrointestinal stromal tumors across various WHO fascicles minimizes potential confusion. The synthesis of morphologic, immunohistochemical, and molecular characteristics in pathologic diagnoses forms the foundation of the clinical decision-making [8]. The WHO classification emerges as a pivotal instrument fostering multidisciplinary collaboration, inviting pathologists, geneticists, and clinicians to integrate their expertise in translating novel pathologic insights into more efficacious treatment avenues.

Four primary challenges are identifiable within the domain of mesenchymal tumors, each contributing to the intricate landscape of diagnosis and treatment [8].

Rarity

The overall incidence of sarcomas is approximately 5 cases per 100,000 individuals, fitting the criteria of a rare tumor [10]. However, within the realm of soft tissue malignancies, there exist around 70 subtypes, each characterized by distinct morphology that often translates into specific clinical behaviors and therapeutic strategies. Furthermore, numerous histotypes are exceedingly rare, even approaching 0.1 cases per 100,000, making encounters with these cases infrequent for pathologists outside high-volume centers [10]. Acquiring specialized expertise becomes a formidable challenge in such a scenario.

Intrinsic Complexity

Mesenchymal tumors exhibit unique diagnostic complexities. The application of malignancy criteria used for epithelial cancers is not universally applicable. Nodular fasciitis serves as a prime example—a benign condition primarily occurring in the forearm of young adults, displaying clinical and pathologic features that, if in an epithelial cancer context, would strongly support malignancy diagnosis [8]. This departure from traditional malignancy criteria is a distinctive trait of mesenchymal tumors and a leading cause of diagnostic inaccuracies.

Technological Complexity

Diagnosing mesenchymal tumors demands a complex fusion of traditional microscopic morphology, immunohistochemistry, and molecular genetics. This necessitates cutting-edge molecular technology, often involving Next Generation Sequencing techniques. Contrary to common perception, molecular genetics requires not only substantial professional expertise but also rigorous quality control standards, surpassing those of immunohistochemistry [8]. Given this context, centralizing molecular diagnostics within high-volume centers is imperative to maintain analytical precision.

Educational Impact

While education remains pivotal in enhancing diagnostic proficiency, its effectiveness in the realm of rare cancers faces limitations. Without continuous exposure to soft tissue tumor diagnostics, the expertise garnered from educational efforts becomes vulnerable to gradual erosion.

The field of sarcoma oncology is dynamically advancing, characterized by an increasingly intimate correlation between pathologic diagnosis and tailored treatments. The WHO classification of soft tissue tumors has undergone transformative evolution since 1999, integrating methodological approaches to

facilitate a more rational therapeutic strategy [9]. Key developments encompass:

Morphology-Immunohistochemistry-Molecular Genetics Integration

Uniting morphology and genetics with the direct association of cytogeneticists stands as a significant leap forward.

Engagement of Expert Pathologists

The involvement of a diverse array of sarcoma expert pathologists curbs the risk of generating “opinion-leader” biases and extends the classification’s reach among pathologists.

Clinicopathological Category Precision

Acknowledgment of an “intermediate” category, distinct from benign and malignant, accommodating lesions that range from locally aggressive (e.g., desmoid fibromatosis) to exceptionally rarely metastasizing (e.g., plexiform fibrohistiocytic tumor) [9].

Clinician Engagement

In the 2020 WHO classification, a fundamental development lies in the direct commitment of clinical representatives from disciplines such as medical, surgical, and radiation oncology [9]. This synergy substantially enhances the clinical value of pathological diagnoses.

Epidemiology and Incidence

Paratesticular mesenchymal chondrosarcomas are exceedingly rare, accounting for a small fraction of all chondrosarcomas. The reported incidence is remarkably low, with only a handful of cases documented in the medical literature. Primary soft tissue sarcomas (STS) originating within the male urinary and genital tract constitute a rare subset of tumors, comprising merely 1% to 2% of all malignancies within the genitourinary (GU) tract, and 7% to 10% of all intrascrotal tumors. The predominant site of origination is para-testicular followed by the prostate/seminal vesicles kidney, bladder, and penis, with over 75% of cases emerging from the spermatic cord [1-11].

Paratesticular sarcomas typically exhibit an aggressive nature marked by a notable prevalence of local recurrence and distant spread [1]. Exploring the clinical management of these sarcomas proves challenging due to their scarcity, leading to treatment recommendations primarily gleaned from small single-institution studies and largely extrapolated from experiences with retroperitoneal sarcomas. This rarity highlights the need for heightened clinical vigilance to accurately diagnose and manage such cases.

Clinical Presentation and Diagnosis

Patients with para-testicular mesenchymal chondrosarcoma is often present with a painless mass in the testicular or para-testicular region. Imaging studies, such as ultrasound and computed tomography, aid in visualizing the extent and characteristics of the mass. Histopathological examination remains the gold standard for diagnosis, revealing the characteristic biphasic pattern of undifferentiated small blue cells and mature hyaline cartilage. Immunohistochemical markers, such as S100, CD99, and Sox9, can further assist in confirming the diagnosis [5].

Histopathology and Molecular Insights

The unique histological composition of para-testicular mesenchymal chondrosarcomas poses challenges in diagnosis and differentiation from other tumors. Recent molecular studies have identified distinct genetic alterations, such as HEY1-NCOA2

fusion, providing potential avenues for targeted therapeutic interventions [12]. The histological diagnosis of mesenchymal chondrosarcoma, particularly in cases where the tumor exhibits minimal cartilaginous components, is often encountered in small biopsies. Within such contexts, distinguishing mesenchymal chondrosarcoma from other round blue cell tumors such as Ewing's sarcoma, rhabdomyosarcoma, small cell osteosarcoma, and desmoplastic round blue cell tumor proves exceedingly intricate. Immunohistochemically, mesenchymal chondrosarcoma manifests positive staining for NKX2.2, CD99, S100, and SOX9 [12]. However, this immune profile is non-specific and overlaps with other round blue cell tumors. Until recently, a dependable immunohistochemical marker to differentiate mesenchymal chondrosarcoma from other round blue cell tumors remained elusive [13,14].

NKX3.1, renowned as a diagnostic biomarker for prostatic adenocarcinoma, has recently emerged as a distinct marker for mesenchymal chondrosarcoma and EWSR1-NFATC2 sarcoma, as recommended by Yoshida et al. in 2020 [15].

Treatment Strategies and Prognosis

The management of para-testicular mesenchymal chondrosarcoma involves a multidisciplinary approach incorporating surgical resection as the cornerstone of treatment. Due to the high propensity for metastasis and limited treatment options early diagnosis and aggressive surgical management are imperative [16,17].

Unfortunately, the prognosis remains unfavorable, with a 5-year survival rate of approximately 43% [10]. Research efforts are ongoing to uncover novel therapeutic targets that could improve patient outcomes [17].

Addressing the Pathology and Mental Well-being

Amid the complexities of managing para-testicular mesenchymal chondrosarcoma, the intertwined challenge of Burnout Syndrome emerges as a critical concern for patients [18]. This rare malignancy's intricate diagnostic process, aggressive behavior, and limited treatment options intensify the emotional strain on patients.

Burnout Syndrome is a condition that can adversely affect patient care and well-being, especially in the case of demanding and uncommon diseases, due to emotional exhaustion, depersonalization, and reduced personal accomplishment [18]. The relationship between patients and caregivers, such as healthcare professionals, can intensify stress, which may result in Burnout Syndrome among caregivers. To address this intricate interplay, it is crucial to adopt a comprehensive strategy that includes disease management and caregiver well-being.

It is imperative to cultivate environments that are conducive to offering support and providing healthcare teams with resources for stress management, as well as psychological support. Providing patients with coping strategies, psychological resources, and mental health support is also crucial [18]. By combining comprehensive disease management with proactive strategies to mitigate Burnout, healthcare professionals can ensure the holistic well-being of patients and caregivers, thereby optimizing patient outcomes and preserving the emotional health of those who are committed to navigating the challenges posed by this uncommon malignancy.

Conclusion

In conclusion, para-testicular mesenchymal chondrosarcoma stands as an uncommon malignancy originating in the para-testicular region, presenting distinct diagnostic and therapeutic complexities. This comprehensive review has illuminated various facets of this entity, including its incidence, epidemiology, clinical presentation, histopathological characteristics, diagnostic modalities, treatment strategies, and prognosis.

The recent advancement in the WHO classification for Soft Tissue Tumors and Bone underscores the significance of refining pathologic diagnoses and therapeutic strategies. The integration of clinical expertise has further underscored the pivotal role of accurate pathologic diagnoses in steering treatment choices. Key developments, such as the risk assessment framework for solitary fibrous tumors, recognition of NTRK-rearranged soft tissue tumors as an "emerging entity," and the classification of undifferentiated round cell sarcomas, epitomize the ongoing efforts in enhancing diagnostic accuracy and treatment efficacy.

The challenges inherent in mesenchymal tumors, encompassing rarity, intrinsic and technological complexities, and limited educational impact, contribute to the intricate landscape of diagnosis and treatment. The epidemiology and incidence of paratesticular mesenchymal chondrosarcomas reveal their scarcity and aggressive behavior, underscoring the need for heightened clinical vigilance.

Clinical presentation and diagnosis emphasize the importance of imaging and histopathological examination, alongside immunohistochemical markers. Advances in molecular insights hold promise for targeted therapeutic interventions, addressing the challenges of diagnosis and differentiation. Treatment strategies, predominantly centered on surgical resection, are complicated by the tumor's metastatic potential, while the unfavorable prognosis underscores the urgency of early detection and aggressive management.

Considering the complexities surrounding para-testicular mesenchymal chondrosarcoma, a comprehensive understanding of its clinical nuances, diagnostic intricacies, and therapeutic options is paramount for healthcare professionals. Continued research endeavors hold the potential to unravel the molecular underpinnings of this entity, opening doors to innovative targeted therapies that could significantly enhance patient prognosis and overall outcomes. In navigating the intricate terrain of para-testicular mesenchymal chondrosarcoma, heightened clinical awareness and ongoing research are the cornerstones for optimizing patient care in the face of this rare malignancy.

References

1. Nodar SR, S Salazar C, Cárdenas, VG Yllán (2022) "Testicular Tumor in Children: A Rare Case Report," *Curr. Pract. Med* 25-34.
2. PC Donoso Mario Paul Sánchez Pérez, Carlos Cárdenas Aguirre, Adriana Ortiz Barbosa, Carmen M Galván Gómez (2022) "Angiosarcoma suprarrenal primario. Reporte de caso," *Arch. Patol* 3: 3-3.
3. SR Nodar, APO Barbosa, BE García, CC Aguirre, JTC Gómez (2022) "Primary Angiosarcoma of the Spleen with Spontaneous Rupture: A Case Report," *Clin. Oncol. Case Rep* Accessed Available: <https://www.scitechnol.com/abstract/primary-angiosarcoma-of-the-spleen-with-spontaneous-rupture-a-case-report-20969.html>.

4. NR Ferrer Maria, Berenguer Romero, Sebastian Ochendusko, Lorena Gomez Perpiña, Stella Pelaez Malagon (2022) "Tumor Fibroso Solitario del Tiroides. Reporte de un caso con hallazgos clínicos y morfológicos inusuales," *Arch. Patol* 3: 3-3
5. C A Cardenas (2023) "Sarcomas: A Comprehensive Review of Classification, Diagnosis, Treatment, and Psychosocial Aspects," *Clin. Oncol. Case Rep* <https://www.scitechnol.com/scholarly/carcinosarcoma-journals-articles-ppts-list.php>.
6. CA Cardenas, S Abrishami (2023) Heartbound Invaders: Reviewing Rare Malignant Carcinomas with Metastatic Fervor to the Heart," *Clin. Oncol. Case Rep* <https://www.scitechnol.com/abstract/heartbound-invaders-reviewing-rare-malignant-carcinomas-with-metastatic-fervor-to-the-heart-22815.html>.
7. C Cardenas (2022) "Extinguishing the unknown from Burnout," *Arch. Patol* <https://www.researchgate.net/profile/Carlos-Cardenas-Aguirre>.
8. ME Kallen, JL Hornick (2021) "The 2020 WHO Classification: What's New in Soft Tissue Tumor Pathology," *Am. J. Surg. Pathol* 45: 1e1-e23.
9. M Sbaraglia, E Bellan, A P Dei Tos (2020) "The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives," *Pathologica* 113: 70-84.
10. L Gatto, Massimo Del Gaudio, Matteo Ravaioli, Matteo Cescon, Valeria Tonini (2020) "Paratesticular Mesenchymal Malignancies: A Single-Center Case Series, Clinical Management, and Review of Literature," *Integr. Cancer Ther* 19: p1534735419900554.
11. C A Cardenas (2022) "The State of Prostate Cancer Around the World - Advances in Prostate Cancer," *Clin. Oncol. Case Rep* <https://www.scitechnol.com/abstract/the-state-of-prostate-cancer-around-the-world--advances-in-prostate-cancer-22812.html>.
12. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data - PubMed <https://pubmed.ncbi.nlm.nih.gov/22034177/>.
13. S R Carlos A (2023) Cardenas, HISTIOCYTIC AND GRANULOMATOUS LESIONS OF THE LUNG FORESC <http://archive.org/details/histiocytic-and-granulomatous-lesions-of-the-lung-rey-cardenas>.
14. SR Carlos Cardenas (2023) DICER 1 GENE Rey Cardenas FORESC <http://archive.org/details/dicer-1-gene-rey-cardenas-2023>.
15. M Syed, S Mushtaq, A Loya, U Hassan (2021) "NKX3.1 a useful marker for mesenchymal chondrosarcoma: An immunohistochemical study," *Ann. Diagn. Pathol* 50: p151660.
16. C A Cardenas (2023) "Cancer Therapeutics: Next-Generation Immunotherapy," *Clin. Oncol. Case Rep* <https://www.scitechnol.com/abstract/cancer-therapeutics-nextgeneration-immunotherapy-23118.html>.
17. C A Cardenas (2023) "Glycolytic Enzyme Enolase-1 (ENO-1) as a Novel Target for Neuroendocrine-Like Prostate Cancer: A Review of Up-to-date Research and Future Prospects," *Clin. Oncol* <https://www.scitechnol.com/abstract/glycolytic-enzyme-enolase1-eno1-as-a-novel-target-for-neuroendocrinlike-prostate-cancer-a-review-of-uptodate-research-and-future-23119.html>.
18. C Cardenas (2022) "Extinguishing the unknown from Burnout," *Arch. Patol* 3: 3-3.

Copyright: ©2023 Carlos Alberto Cardenas. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.